Recurrent WHO Grade 2 Glioma

1

Review clinical trials related to Recurrent WHO Grade 2 Glioma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Northwestern UniversityUpdated: May 1, 2026Locations: 1
Eligibility criteria

Patients must have histologically confirmed World Health Organization (WHO) grad... [+28]

Patients who have a prior or concurrent malignancy that may interfere with study... [+24]